Literature DB >> 10691892

Interleukin-13 and tumour necrosis factor-alpha synergistically induce eotaxin production in human nasal fibroblasts.

N Terada1, N Hamano, T Nomura, T Numata, K Hirai, T Nakajima, H Yamada, O Yoshie, T Ikeda-Ito, A Konno.   

Abstract

BACKGROUND: There is increasing evidence that eotaxin is a key mediator in the development of tissue eosinophilia. However, the mechanism involved in the production of eotaxin has yet to be clarified. Most recently, it has been shown that interleukin (IL) -4 induces eotaxin in dermal fibroblasts. A novel cytokine termed IL-13, which binds to the alpha-chain of the IL-4 receptor, shares many biological activities with IL-4. It is known that fibroblasts express the IL-4 receptor and produce collagen type I upon stimulation with IL-4.
OBJECTIVE: We investigated whether IL-13, as well as IL-4, are able to induce eotaxin production in human nasal mucosal fibroblasts (HNMFs). Furthermore, we investigated the effect of costimulation of IL-13 and TNFalpha on eotaxin production.
METHODS: HNMFs, isolated from inferior nasal mucosa samples, were stimulated by various kind of cytokines for 1-36 h at 37 degrees C in 5% CO2. The change in the expression of eotaxin mRNA was then evaluated by reverse transcriptase-polymerase chain reaction and the Southern blot analysis. The amount of eotaxin in the culture media was measured by ELISA.
RESULTS: IL-13 as well as IL-4 dose-dependently induced eotaxin expression in HNMFs. Furthermore, IL-13 and TNFalpha synergistically induced eotaxin expression in HNMFs, while they hardly induced eotaxin expression in endothelial cells, epithelial cells or eosinophils. The synergy was observed when pre-incubation of HNMFs with IL-13 was followed by a stimulation with TNFalpha, or HNMFs were simultaneously stimulated with IL-13 and TNFalpha.
CONCLUSION: These results strongly indicate that IL-13, as well as IL-4, may be important in eotaxin-mediated eosinophilic inflammation in nasal mucosa. In addition, in nasal mucosa, fibroblasts are the major cell source for eotaxin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10691892     DOI: 10.1046/j.1365-2222.2000.00750.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  8 in total

1.  Cysteinyl-leukotriene type 1 receptors transduce a critical signal for the up-regulation of eosinophilopoiesis by interleukin-13 and eotaxin in murine bone marrow.

Authors:  Tulio Queto; Maria I Gaspar-Elsas; Daniela Masid-de-Brito; Zilton F M Vasconcelos; Fausto K Ferraris; Carmen Penido; Fernando Q Cunha; Yoshihide Kanaoka; Bing K Lam; Pedro Xavier-Elsas
Journal:  J Leukoc Biol       Date:  2010-03-10       Impact factor: 4.962

2.  SPLUNC1 deficiency enhances airway eosinophilic inflammation in mice.

Authors:  Jyoti V Thaikoottathil; Richard J Martin; Peter Y Di; Maisha Minor; Stephanie Case; Bicheng Zhang; Gongyi Zhang; Hua Huang; Hong Wei Chu
Journal:  Am J Respir Cell Mol Biol       Date:  2012-04-12       Impact factor: 6.914

Review 3.  Regulation of allergic airways inflammation by cytokines and glucocorticoids.

Authors:  L Cameron; Q Hamid
Journal:  Curr Allergy Asthma Rep       Date:  2001-03       Impact factor: 4.806

Review 4.  The potential for genetically altered microglia to influence glioma treatment.

Authors:  W Li; R M D Holsinger; C A Kruse; A Flügel; M B Graeber
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-09       Impact factor: 4.388

5.  Low concentrations of cytokines produced by allergen-stimulated peripheral blood mononuclear cells have potent effects on nasal polyp-derived fibroblasts.

Authors:  S Olsson; F Cagnoni; P Dignetti; G Melioli; G W Canonica
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

6.  MAPK regulation of IL-4/IL-13 receptors contributes to the synergistic increase in CCL11/eotaxin-1 in response to TGF-β1 and IL-13 in human airway fibroblasts.

Authors:  Xiuxia Zhou; Haizhen Hu; Silvana Balzar; John B Trudeau; Sally E Wenzel
Journal:  J Immunol       Date:  2012-05-09       Impact factor: 5.422

7.  Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma.

Authors:  R D May; P D Monk; E S Cohen; D Manuel; F Dempsey; N H E Davis; A J Dodd; D J Corkill; J Woods; C Joberty-Candotti; L A Conroy; F Koentgen; E C Martin; R Wilson; N Brennan; J Powell; I K Anderson
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

8.  Gene expression profiling following NRF2 and KEAP1 siRNA knockdown in human lung fibroblasts identifies CCL11/Eotaxin-1 as a novel NRF2 regulated gene.

Authors:  Jimmy Fourtounis; I-Ming Wang; Marie-Claude Mathieu; David Claveau; Tenneille Loo; Aimee L Jackson; Mette A Peters; Alex G Therien; Yves Boie; Michael A Crackower
Journal:  Respir Res       Date:  2012-10-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.